NCT01529437View on ClinicalTrials.gov

Sublingual Immunotherapy Studies for Grass and Dust Mite Allergies

PHASE1CompletedINTERVENTIONAL
Enrollment

31

Participants

Timeline

Start Date

January 31, 2005

Primary Completion Date

January 31, 2014

Study Completion Date

January 31, 2014

Conditions
AllergiesAllergic RhinitisAsthma
Interventions
DRUG

sublingual immunotherapy

Sublingual immunotherapy is provided in an extract form under IND 13485 and dosed safely through a maintenance dose of 12 months.

DRUG

placebo sublingual immunotherapy

SLIT placebo will be the same color and consistency of the active drug arm to provide double blinding

Trial Locations (1)

94305

Stanford University, Stanford

All Listed Sponsors
lead

Stanford University

OTHER

NCT01529437 - Sublingual Immunotherapy Studies for Grass and Dust Mite Allergies | Biotech Hunter | Biotech Hunter